阿仑膦酸钠联合骨肽治疗骨质疏松症患者的临床效果

发布时间：2018-03-16 22:51

本文选题：骨质疏松　切入点：阿仑膦酸钠　出处：《中国骨质疏松杂志》2017年06期 　论文类型：期刊论文

【摘要】：目的分析骨质疏松症患者使用阿仑膦酸钠联合骨肽注射液治疗的临床效果和影响。方法将我院2013年5月-2015年8月收治的500例骨质疏松症患者作为分析对象,按照随机分组方式分成对照组和试验组各250例,对照组患者采取阿仑膦酸钠治疗骨质疏松症,而试验组患者在对照组基础之上联合骨肽注射液治疗骨质疏松症,对比两组患者的临床治疗总有效率、治疗前后股骨密度的改善情况和临床不良反应率。结果对照组患者的临床治疗总有效率(72.0%)明显低于试验组(96.80%),差异具有统计学意义(P0.05);试验组患者在治疗后骨密度情况明显优于对照组;试验组患者的临床不良反应率(6.80%)明显优于对照组(40.0%),组间差异具有统计学意义(P0.05)。结论骨质疏松症患者使用阿仑膦酸钠联合骨肽注射液治疗的临床效果良好,可以有效提高患者的骨密度。
[Abstract]:Objective to analyze the patients with osteoporosis with alendronate combined with ossotide injection in the treatment of the clinical effect and influence as the analysis objects. Methods 500 cases of osteoporosis patients in our hospital in May 2013 -2015 year in August, according to randomly divided into control group and experimental group with 250 cases in each group, the control group were treated with alendronate sodium in the treatment of osteoporosis, while the experimental group in the control group on the basis of ossotide injection in the treatment of osteoporosis, clinical treatment were compared between two groups of the total efficiency rate of the femoral BMD improvement and clinical adverse reactions before and after treatment. The clinical results in the control group the total efficiency (72%) was significantly lower than the test group (96.80%), the difference was statistically significant (P0.05); patients in the experimental group after treatment, the bone density was significantly better than the control group; the clinical adverse reactions in experimental group was significant (6.80%) Better than the control group (40%), a statistically significant difference between the groups (P0.05). Conclusion the clinical effect of osteoporosis with alendronate combined with ossotide injection treatment, can effectively improve the patients with bone mineral density.

【作者单位】：河南省人民医院;
【基金】：河南省医学重点学科临床特色专科学术技术带头人出国培训计划项目(2014095)
【分类号】：R580

【相似文献】